Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in β-amyloid-treated C6 glioma cells

International Journal of Molecular Medicine

Volumn 17, Issue 6, 2006, Pages 1069-1075

  Kim, Young Ae ^a,c   Lim, Sun Young ^d   Rhee, Sook Hee ^c   Park, Kun Young ^c   Kim, Cheorl Ho ^e   Choi, Byung Tae ^a   Lee, Su Jae ^f   Park, Yeong Min ^g   Choi, Yung Hyun ^a,b  

^a Dong Eui University   (South Korea)

^b Dong Eui University   (South Korea)

^c Pusan National University   (South Korea)

^d Korea Maritime University   (South Korea)

^e Dongguk University   (South Korea)

^f Korea Institute of Radiation and Medical Science   (South Korea)

^g Pusan National University School of Medicine   (South Korea)

Author keywords

COX 2; iNOS; NF B; Resveratrol; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; ANTIOXIDANT; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NEUROPROTECTIVE AGENT; PROSTAGLANDIN E2; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; ARTICLE; BIOSYNTHESIS; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; GLIA; GLIOMA; METABOLISM; PROTEIN TRANSPORT; RAT; TRANSACTIVATION; TUMOR CELL LINE;

AMYLOID BETA-PROTEIN; ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DINOPROSTONE; DOWN-REGULATION; GLIOMA; NEUROGLIA; NEUROPROTECTIVE AGENTS; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN TRANSPORT; RATS; STILBENES; TRANS-ACTIVATION (GENETICS);

EID: 33745727518     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.17.6.1069     Document Type: Article

References (43)

1. Selkoe DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399: A23-A31, 1999.
2. Butterfield DA, Castegna A, Lauderback CM and Drake J: Evidence that amyloid β-peptide-induced lipid peroxidation and its sequel in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 23: 655-664, 2002.
3. Eckert A, Keil U, Marques CA, Bonert A, Frey C, Schussel K and Muller WE: Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol 66: 1627-1634, 2003. (Pubitemid 38373355)
4. Canevari L, Abramov AY and Duchen MR: Toxicity of amyloid β peptide: tales of calcium, mitochondria, and oxidative stress. Neurochem Res 29: 637-650, 2004. (Pubitemid 38295014)
5. Grundman M, Grundman M and Delaney P: Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc 61: 191-202, 2002.
6. Komatsu M and Hiramatsu M: The efficacy of an antioxidant cocktail on lipid peroxide level and superoxide dismutase activity in aged rat brain and DNA damage in iron-induced epileptogenic foci. Toxicology 148: 143-148, 2000.
7. Bastianetto S, Zheng WH and Quirion R: Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br J Pharmacol 131: 711-720, 2000.
8. Soleas GJ, Diamandis EP and Goldberg DM: Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal 11: 287-313, 1997.
9. Frémont L: Biological effects of resveratrol. Life Sci 66: 663-673, 2000.
10. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC and Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997.
11. Belguendouz L, Frémont L and Linard A: Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol 53: 1347-1355, 1997.
12. Ciolino HP, Daschner PJ and Yeh GC: Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 58: 5707-5712, 1998.
13. Martinez J and Moreno JJ: Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol 59: 865-870, 2000.
14. Bertelli AA, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M and Bertelli A: Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 17: 1-3, 1995.
15. Frankel EN, Waterhouse AL and Kinsella JE: Inhibition of human LDL oxidation by resveratrol. Lancet 341: 1103-1104, 1993.
16. Jayatilake GS, Jayasuriya H, Lee ES, Koonchanok NM, Geahlen RL, Ashendel CL, McLaughlin JL and Chang CJ: Kinase inhibitors polygonum cuspidatum. J Nat Prod 56: 1805-1810, 1993.
17. Fontecave M, Le Piovre M, Elleingand E, Gerez C and Guittet O: Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 421: 277-279, 2000. (Pubitemid 28045770)
18. Sun N, Woo SH, Cassady JM and Snapka RM: DNA polymerase and topoisomerase II inhibitors from Psorealea corylifolia. J Nat Prod 61: 362-366, 1998.
19. Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu ML, Takano E, Maki M, Henkart PA and Trepel JB: Regulation of cyclin D1 by calpain protease. J Biol Chem 272: 28479-28484, 1997.
20. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM and Dannenberg AJ: Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 273: 21875-21882, 1998. (Pubitemid 28405365)
21. Jang M and Pezzuto JM: Effects of resveratrol on 12-O- tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin. Cancer Lett 134: 81-89, 1998.
22. Jang JH and Surh YJ: Protective effect of resveratrol on β-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med 34: 1100-1110, 2003.
23. Han YS, Zheng WH, Bastianetto S, Chabot JG and Quirion R: Neuroprotective effects of resveratrol against β-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol 141: 997-1005, 2004.
24. Hardy JA and Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185, 1992.
25. Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, Oster-Granite ML and Neve RL: Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245: 417-420, 1989. (Pubitemid 19203368)
26. Eikelenboom P and van Gool WA: Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J Neural Transm Suppl 111: 281-294, 2004.
27. Raivich G, Jones LL, Werner A, Bluthmann H, Doetschmann T and Kreutzberg GW: Molecular signals for glial activation: pro- and anti-inflammatory cytokines in the injured brain. Acta Neurochir 73: S21-S30, 1999.
28. Pasinetti GM: From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in β-amyloidosis and clinical dementia. Alzheimers Dis 4: 435-445, 2002.
29. Hoozemans JJ, Rozemuller AJ, Janssen I, De Groot CJ, Veerhuis R and Eikelenboom P: Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol 101: 2-8, 2001.
30. 2 levels in patients with probable AD. Neurology 53: 1495-1498, 1999.
31. Duncan AJ and Heales SJ: Nitric oxide and neurological disorders. Mol Aspects Med 26: 67-96, 2005.
32. Seyidova D, Aliyev A, Rzayev N, Obrenovich M, Lamb BT, Smith MA, De la Torre JC, Perry G and Aliev G: The role of nitric oxide in the pathogenesis of brain lesions during the development of Alzheimer's disease. In Vivo 18: 325-333, 2004.
33. MacMicking J, Xie QW and Nathan C: Nitric oxide and macrophage function. Annu Rev Immunol 15: 323-350, 1997.
34. Liu RH and Hotchkiss JH: Potential genotoxicity of chronically elevated nitric oxide: A review. Mutat Res 339: 73-89, 1995.
35. Alderton WK, Cooper CE and Knowles RG: Nitric oxide synthases: structure, function and inhibition. Biochem J 357: 593-615, 2001.
36. Janssen-Heininger YM, Poynter ME and Baeuerle PA: Recent advances towards understanding redox mechanisms in the activation of nuclear factor κB. Free Radic Biol Med 28: 1317-1327, 2000.
37. Tazawa R, Xu XM, Wu KK and Wang LH: Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun 203: 190-199, 1994. (Pubitemid 24281079)
38. Xie QW, Kashiwabara Y and Nathan C: Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J Biol Chem 269: 4705-4708, 1994. (Pubitemid 24239438)
39. Tak PP and Firestein GS: NF-κB: a key role in inflammatory diseases. J Clin Invest 107: 7-11, 2001.
40. Baeuerle PA and Baltimore D: NF-κB: ten years after. Cell 87: 13-20, 1996.
41. Terai K, Matsuo A and McGeer PL: Enhancement of immunoreactivity for NF-κB in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res 735: 159-168, 1996.
42. Akama KT and van Eldik LJ: β-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1β- and tumor necrosis factor-α (TNFα)-dependent, and involves a TNFα receptor-associated factor- and NF-κB-inducing kinase-dependent signaling mechanism. J Biol Chem 275: 7918-7924, 2000.
43. Jang JH and Surh YJ: β-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-κB signaling pathway. Free Radic Biol Med 38: 1604-1613, 2005.